Vita Life Sciences (VLS) H2 2025 earnings summary

Executive summary

• Revenue reached a record $93.3m, up 17.3% year-over-year, with net profit after tax rising 18.8% to $10.4m.

• Operating cash flow before interest and tax was $18.4m, and the group remained debt free with net assets of $56.2m.

• Dividend for FY2025 totaled 14.0 cents per share, marking the 16th consecutive year of payments, with a payout ratio of 75%.

• Positive trading conditions and diversified geographic footprint supported consistent performance and long-term growth investments.

Financial highlights

• EBITDA increased 19.1% to $14.8m, and EPS rose 16.7% to 18.63 cents per share year-over-year.

• Cash and cash equivalents grew to $35.6m from $28.6m, and total assets increased to $82.4m.

• Dividends declared rose 40% to 14.0 cents per share compared to the prior year.

• Net tangible assets per share increased to $1.01 from $0.94.

Outlook and guidance

• The company enters 2026 well positioned, with ongoing strategic investments in brand development and channel expansion.

• Continued focus on geographic and channel diversification to support resilience and growth.